Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone prodrug is a small molecule therapeutic developed by Rusan Healthcare, specifically designed for the treatment of opioid and alcohol dependence. It serves as a precursor to naltrexone, a potent opioid receptor antagonist. By blocking mu-opioid receptors, the drug inhibits the reinforcing effects of opioids and reduces alcohol cravings, facilitating long-term abstinence. This prodrug formulation is typically engineered for long-term release, often as a depot injection, to overcome the compliance challenges associated with daily oral naltrexone therapy. It is currently approved for use in managing substance use disorders in specific jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naltrexone prodrug.